Using Synthace to Develop Advanced Therapies – with Oxford Biomedica

Expert Spotlight Webinar

Oxford Biomedica have utilized Synthace to perform Design of Experiments (DOE) optimization of their in-house lentiviral vector production for advanced therapeutics. This resulted in 3-10 fold increase in vector titre40 hours full time equivalent saving and 81% reduction in pure error.

To see the data behind this, learn more about the productivity gains enabled by automation, understand how Synthace empowers scientists to perform sophisticated multifactorial experiments, and hear how it has benefited Oxford Biomedica in creating their lab of the future, watch the on-demand recoding now.

  • Learn how you can easily perform sophisticated multifactorial experiments with Synthace to optimize your bioprocess

  • See the data behind the 3-10 fold increase in vector titre, 40 hours full time equivalent saving and 81% reduction in pure error achieved with Synthace

  • Hear how Synthace is being used by Oxford Biomedica as they implement their lab of the future

WEBINAR PREVIEW

The webinar covered the key results, ROI's and methodology featured in our case study with Oxford Biomedica in which they used Synthace to improve the efficiency and robustness of their in-house lentiviral vector production through optimization of their transfection reagent mixes. The speakers discussed how the implementation of an automated multifactorial (DOE) approach enabled this, before speaking about how they are continuing to work with Synthace as they further optimize their upstream bioprocess.

In the case study, Synthace enabled 3x the sophistication of the DOE that could be run compared to manual pipetting, whilst also enabling the scientist to design and execute the experiment 5x faster than if they self-programmed a liquid handling robot.

Speakers

André Raposo

Group Lead - Computer-Aided Biology (CAB) Group, Oxford Biomedica

Thomas Evans

Senior Scientist, Oxford Biomedica

Markus Gershater
Markus Gershater

Chief Scientific Officer and Co-Founder

🔝